Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Clavreul, Anne, Roger, Emilie, Pourbaghi-Masouleh, Milad, Lemaire, Laurent, Tétaud, Clément, Menei, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225440/
https://www.ncbi.nlm.nih.gov/pubmed/30338715
http://dx.doi.org/10.1080/10717544.2018.1507061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225440/
https://www.ncbi.nlm.nih.gov/pubmed/30338715
http://dx.doi.org/10.1080/10717544.2018.1507061

Ejemplares similares